-
361 Reads
|
1 Comment
|
April 1, 2014
-
311 Reads
|
0 Comments
|
April 1, 2014
More from Fred In answer to my assumptions and questions and several emails so the answers may again seem a bit disjointed! I hate to admit my ignorance but I did not realize we had so many drug products under way. ************************************ "NantPharma has increased its ownership stakes in NantPro following the development work funded over the last months. If...
-
366 Reads
|
0 Comments
|
March 31, 2014
Good news for PLI on Halozyme.... Halozyme news:Looks like Halo is now advancing their injection process, which uses PLI's technology, thru the FDA and has had a successful first trial. Anything good for halo is good for PLI. HALO | 8 minutes ago SAN DIEGO, March 31, 2014 /PRNewswire/ -- Halozyme Therapeutics, Inc...
-
403 Reads
|
0 Comments
|
March 28, 2014
Investment recommendation ProMetic reported Q4 results that were modestly below expectations. Revenue declined 39.0% YoY to $5.1 million, and EBITDA of ($3.8) million was below our estimate of ($0.7) million on higher R&D spending. The stock has been under pressure recently on little news, likely caught in a downdraft for biotech valuations. With a number of near-term potential catalysts...
-
314 Reads
|
0 Comments
|
March 27, 2014
Paradigms comments in previous post. Although we don’t believe in timing the market or panicking over market movements, we do like to keep an eye on big changes — just in case they’re material to our investing thesis. What: Shares of ProMetic Life Sciences (TSX: PLI) soared 12% today after the biopharmaceutical company’s quarterly results impressed Bay...
-
345 Reads
|
0 Comments
|
March 27, 2014
Paradigm's take on Q4/2013 Subject: Prometic (PLI-T): Initial Take-Away from Q4 Results is Positive for Long-term EVENT PLI’s Q4 is out – Revenue generally in line, Increased R&D investment led to a miss on EBITDA DETAILS · Reported numbers are...
-
435 Reads
|
0 Comments
|
March 27, 2014
Thanks Sah, fokkin missed that on 4050! You are right. This PR is much stronger than expectEd. It implies Phase I results on 4050 have been successful otherwise there would be no initiation in diabetic patients with CKD in H2. Also, the filing of the IND on plasminogen will be straight forward as the regulatory pathway has been approved by the FDA. both the...
-
319 Reads
|
0 Comments
|
March 21, 2014
'stability' of the plasma fraction business Staghorn, you have absolutely nailed it. It is because of the 'stability' of the plasma fractionation business that analysts view PLI to be a low risk/high return stock. PPPS is best of class technology and offers huge potential for growth in two areas. First, PPPS can selectively extract valuable therapeutic proteins at...